Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Rises By 90.3%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 457,500 shares, a growth of 90.3% from the December 15th total of 240,400 shares. Based on an average trading volume of 3,640,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 3.2% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, Maxim Group reissued a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, October 9th.

Hedge Funds Weigh In On Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. 32.23% of the stock is owned by institutional investors.

Virpax Pharmaceuticals Trading Down 2.4 %

NASDAQ VRPX opened at $0.36 on Tuesday. Virpax Pharmaceuticals has a 12 month low of $0.29 and a 12 month high of $5.48. The company’s 50 day simple moving average is $0.46 and its 200 day simple moving average is $0.73.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.